Search

There's more than one way to skin a cat. This famous, 17th century English proverb is applicable to just about every experience, encounter and undertaking in life--including eye care. While [...]

AGE RELATED MACULAR degeneration (AMD) is the leading cause of vision loss among older Americans, with over ten million suffering from the disorder and nearly two million suffering with wet [...]

Background: Lutein and docosahexaenoic acid (DHA) may protect against age-related macular degeneration (AMD). Lutein is a component of macular pigment. DHA is in the retina. Objective: The objective of this 4-mo study was to determine the effects of lutein (12 mg/d) and DHA (800 mg/d) on their serum concentrations and macular pigment optical density (MPOD). Design: Forty-nine women (60-80 y) were randomly assigned to placebo, DHA, lutein, or lutein + DHA supplement. Serum was analyzed for lutein and DHA (0, 2, and 4 mo). MPOD was determined (0 and 4 mo) at 0.4, 1.5, 3, and 5[degrees] temporal retinal eccentricities. Serum was analyzed for lipoproteins (4 mo). Results: There was no interaction between lutein and DHA supplementations for serum lutein and MPOD. The lutein supplementation x DHA supplementation x month interaction was significant for serum DHA response (P < 0.05). In the lutein group, serum lutein increased from baseline at 2 and 4 mo (P < 0.001), and MPOD increased at 3.0[degrees] (P < 0.01). In the DHA group, serum DHA increased at 2 and 4 mo (P < 0.0001), and MPOD increased at 0.4[degrees] (P < 0.05). In the lutein + DHA group, serum lutein and DHA increased at 2 and 4 mo (P < 0.01), and MPOD increased at 0.4, 1.5, and 3[degrees] (P = 0.06, 0.08, and 0.09, respectively). Differences from placebo in lipoprotein subfractions were greatest for the lutein + DHA group (4 mo). Conclusions: Lutein supplementation increased MPOD eccentrically. DHA resulted in central increases. These results may be due to changes in lipoproteins. Lutein and DHA may aid in prevention of age-related macular degeneration.

In the United States, age-related macular degeneration (AMD) is the leading cause of blindness in the elderly population. (1) AMD causes visual impairment in an estimated 1.7 million Americans over [...]

Practice recommendations * Advanced age, positive family history, smoking, hypertension, and Caucasian ancestry are risk factors consistently associated with age-related macular degeneration (ARMD). * With older patients, suspect ARMD if [...]

Eleven years ago, then 39-year-old Chip Goehring of Doylestown, Pa., saw his ophthalmologist for his regular yearly checkup (he is near-sighted), when his doctor diagnosed him with dry age-related macular [...]

When new technology can impact an entire generation of patients, optometrists have an opportunity to change. Such was the case a generation ago in glaucoma with functional testing (automated perimetry), [...]

Age-related retinal disease, comprising age-related maculopathy (ARM) and age-related macular degeneration (AMD) is the leading cause of blindness and visual disability among the aging in the Western hemisphere. About 1.8 [...]

THOUGH THE DILATED clinical fundus examination is considered the standard of care for preoperative evaluation of the macula, its limited ability to detect pathology in patients with opaque media is [...]

As the second private practice clinician to own an AdaptDx, I have more than four years of experience with the device. First and foremost, the AdaptDx has dramatically improved my [...]

They say old habits die hard, but when new technology has the ability to impact an entire generation of patients, optometrists have the opportunity to utilize instruments of change. Such [...]

A 63-year-old Hispanic female presented for an annual eye exam with a chief complaint of blurred vision in her right eye. She has been a patient in the primary eye [...]

A 25-year-old white female presented for an eye examination after she failed the required vision test for obtaining her driver's license. She reported that she had "vision difficulties" for as [...]

Age-related macular degeneration (AMD) causes loss of vision in people over 60 years of age. Issues such as when to suspect a patient has AMD, how to care for, and what to teach the patient about the disease are discussed, with a focus on the new treatments and adverse reactions.

A 62-year-old white male presented for a second opinion about the decreased vision in his left eye. He said that his vision loss occurred suddenly one year ago without pain [...]

Byline: Vikas. Tah, Pearce. Keane, Simona. Esposti, Joseph. Allimuthu, Fred. Chen, Lyndon. Cruz, Adnan. Tufail, Praveen. Patel Introduction: Optical coherence tomography (OCT) is a commonly used imaging modality that provides [...]

Researchers identify potential biomarkers of age-related macular degeneration. Patients with any stage of age-related macular degeneration (AMD) carry signs of the disease in their blood that may be found through [...]

Practitioners from around the UK braved the snowy conditions to converge on Silverstone racing track earlier this week to hear about OCTs.The event, organised by the National Eyecare Group (NEG), [...]

Earlier this year, I presented a lecture on age-related macular degeneration (AMD) to a large group of fellow optometrists. During the lecture, I asked the audience how many of them [...]

Information on age-related macular degeneration in early, intermediate and advanced form, that causes blindness, and its treatment is presented.

In the third of our eye care pathway-related CET articles, Dr Frank Eperjesi and Hannah Bartlett describe the various risk factors, some controllable, for this common eye disease. CET module [...]

Bill Harvey takes a look at the aims of the proposed pathway for improved service to those found to have the most common cause of registerable sight loss in the [...]

Tom Bremridge, chief executive of the Macular Disease Society, describes the work of the charity which represents the largest patient group for visually impaired people In 1987 a newly diagnosed [...]